Skip to main content

People in the News: Feb 26, 2009

Premium

Merck said that its directors have nominated Thomas Cech to join the company's board.

Cech, who will stand for election by Merck shareholders in April, is currently president of the Howard Hughes Medical Institute. He is slated to step down from the position in March, when he will return to a faculty position at the University of Colorado, Boulder.

Cech is a co-founder of Ribozyme Pharmaceuticals, which later became Sirna Therapeutics. Merck acquired Sirna in 2006.


Flamel Technologies, a developer of drug-delivery technologies, has appointed Jeffery Vick as its CBO.

Vick previously served as CEO of Silence Therapeutics.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.